Literature DB >> 20630074

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient.

Marios E Froudarakis1, Evangelos Briasoulis.   

Abstract

Entities:  

Year:  2010        PMID： 20630074      PMCID： PMC2914654          DOI： 10.1186/1756-0500-3-195

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN： 1756-0500


× No keyword cloud information.
  24 in total

1.  Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.

Authors:  Thomas A Hensing; Michael J Schell; Ji-Hyun Lee; Mark A Socinski
Journal:  Lung Cancer       Date:  2005-02       Impact factor: 5.705

2.  Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?

Authors:  Chih-Hsin Yang
Journal:  J Chin Med Assoc       Date:  2005-04       Impact factor: 2.743

3.  Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.

Authors:  Massimo Di Maio; Nicola Lama; Alessandro Morabito; Egbert F Smit; Vassilis Georgoulias; Koji Takeda; Elisabeth Quoix; Dora Hatzidaki; Floris M Wachters; Vittorio Gebbia; Chun-Ming Tsai; Carlos Camps; Wolfgang Schuette; Paolo Chiodini; Maria Carmela Piccirillo; Francesco Perrone; Ciro Gallo; Cesare Gridelli
Journal:  Eur J Cancer       Date:  2010-01-04       Impact factor: 9.162

Review 4.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

5.  Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.

Authors:  Evangelos Briasoulis; Periklis Pappas; Christian Puozzo; Christos Tolis; George Fountzilas; Urania Dafni; Marios Marselos; Nicholas Pavlidis
Journal:  Clin Cancer Res       Date:  2009-10-06       Impact factor: 12.531

6.  Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.

Authors:  Adeel Sabir; Rachel Schor-Bardach; Carol J Wilcox; Syed Rahmanuddin; Michael B Atkins; Jonathan B Kruskal; Sabina Signoretti; Vassilios D Raptopoulos; S Nahum Goldberg
Journal:  AJR Am J Roentgenol       Date:  2008-07       Impact factor: 3.959

Review 7.  Second-line chemotherapy for non-small cell lung cancer.

Authors:  X Bonfill; C Serra; M Sacristán; M Nogué; F Losa; J Montesinos
Journal:  Cochrane Database Syst Rev       Date:  2002

8.  Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

Authors:  Alex A Adjei; Sumithra J Mandrekar; Grace K Dy; Julian R Molina; Araba A Adjei; David R Gandara; Katie L Allen Ziegler; Philip J Stella; Kendrith M Rowland; Steven E Schild; Ralph G Zinner
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

Review 9.  Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitrios Bafaloukos; Paris Kosmidis; Samuel Murray
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

10.  Second-line treatment of advanced non-small cell lung cancer.

Authors:  Cesare Gridelli; Andrea Ardizzoni; Fortunato Ciardiello; Nasser Hanna; John V Heymach; Francesco Perrone; Rafael Rosell; Frances A Shepherd; Nick Thatcher; Johan Vansteenkiste; Luigi De Petris; Massimo Di Maio; Filippo De Marinis
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609
View more
  2 in total

1.  Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observations.

Authors:  Hyun J Bang; Peter J Littrup; Brandt P Currier; Dylan J Goodrich; Hussein D Aoun; Lydia C Klein; Jarret C Kuo; Lance K Heilbrun; Shirish Gadgeel; Allen C Goodman
Journal:  J Vasc Interv Radiol       Date:  2012-06       Impact factor: 3.464

2.  RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse.

Authors:  Jaebeom Cho; Hye-Young Min; Ho Jin Lee; Seung Yeob Hyun; Jeong Yeon Sim; Myungkyung Noh; Su Jung Hwang; Shin-Hyung Park; Hye-Jin Boo; Hyo-Jong Lee; Sungyoul Hong; Rang-Woon Park; Young Kee Shin; Mien-Chie Hung; Ho-Young Lee
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.